CN111615513A - C5a受体调节剂 - Google Patents

C5a受体调节剂 Download PDF

Info

Publication number
CN111615513A
CN111615513A CN201980008986.8A CN201980008986A CN111615513A CN 111615513 A CN111615513 A CN 111615513A CN 201980008986 A CN201980008986 A CN 201980008986A CN 111615513 A CN111615513 A CN 111615513A
Authority
CN
China
Prior art keywords
methoxy
dihydro
benzyl
trifluoromethyl
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980008986.8A
Other languages
English (en)
Chinese (zh)
Inventor
塞尔维·弗里德沃克斯
弗朗西斯·胡伯勒
马克·马菲
多特·伦内贝格
西蒙·斯塔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN111615513A publication Critical patent/CN111615513A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201980008986.8A 2018-01-19 2019-01-18 C5a受体调节剂 Pending CN111615513A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2018051278 2018-01-19
EPPCT/EP2018/051278 2018-01-19
PCT/EP2019/051230 WO2019141803A1 (en) 2018-01-19 2019-01-18 C5a receptor modulators

Publications (1)

Publication Number Publication Date
CN111615513A true CN111615513A (zh) 2020-09-01

Family

ID=65023914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980008986.8A Pending CN111615513A (zh) 2018-01-19 2019-01-18 C5a受体调节剂

Country Status (6)

Country Link
US (1) US11739070B2 (cg-RX-API-DMAC7.html)
EP (1) EP3740476A1 (cg-RX-API-DMAC7.html)
JP (1) JP7281469B2 (cg-RX-API-DMAC7.html)
CN (1) CN111615513A (cg-RX-API-DMAC7.html)
CA (1) CA3087886A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019141803A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124694C2 (uk) 2018-01-10 2021-10-27 Ідорсія Фармасьютікалз Лтд 2,4,6,7-ТЕТРАГІДРОПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ОНОВІ ПОХІДНІ ТА СПОРІДНЕНІ СПОЛУКИ ЯК МОДУЛЯТОРИ РЕЦЕПТОРА C5A ДЛЯ ЛІКУВАННЯ ВАСКУЛІТУ ТА ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
WO2019141803A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
DK3808747T3 (da) * 2018-09-13 2025-02-03 Kissei Pharmaceutical Imidazopyridinon-forbindelse
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法
KR20240021883A (ko) 2021-06-16 2024-02-19 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 기를 포함하는 아제티디닐 화합물
WO2026013291A1 (en) * 2024-07-11 2026-01-15 University Of Dundee Inhibitors of rna methyltransferase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51125286A (en) * 1975-02-14 1976-11-01 Yoshitomi Pharmaceut Ind Ltd A process for preparing novel 3- substituted n-benzylpyrrolidine deriv atives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722190B1 (fr) 1994-07-05 1996-10-04 Sanofi Sa Derives de 1-benzyl-1,3-dihydro-2h-benzimidazol-2-one, leur preparation, les compositions pharmaceutique en contenant
PL342046A1 (en) 1998-01-19 2001-05-21 Pfizer 4-(2-keto-1-benzimidazolinyl)piperidine compounds as agonists of orl1 receptor
KR100607634B1 (ko) 1998-10-16 2006-08-02 다이닛본 스미토모 세이야꾸 가부시끼가이샤 퀴나졸리논 유도체
PL347432A1 (en) 1998-10-23 2002-04-08 Hoffmann La Roche Bicyclic nitrogen heterocycles
TR200200161T2 (tr) 1999-07-21 2002-05-21 Fujisawa Pharmaceutical Co. Ltd. Benzimidazol türevleri ve onların fosfodiesteraz olarak kullanımı.
AU2001238690A1 (en) 2000-03-14 2001-09-24 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
CN100360130C (zh) 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1-(4-哌啶基)苯并咪唑酮
JP2007515458A (ja) 2003-12-23 2007-06-14 テイボテク・フアーマシユーチカルズ・リミテツド Hivプロテアーゼ阻害剤の自己ミクロ乳化性薬剤送達システム
ATE518840T1 (de) 2007-05-22 2011-08-15 Boehringer Ingelheim Int Benzimidazolonchymasehemmer
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
US20120143725A1 (en) 2010-12-02 2012-06-07 Vinimaya Inc. Methods and systems for influencing search and shopping decisions in electronic procurement
GB201106814D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compounds
MX2016002544A (es) 2013-09-04 2016-06-17 Squibb Bristol Myers Co Compuestos utiles como inmunomoduladores.
RS57508B1 (sr) 2013-09-06 2018-10-31 Aurigene Discovery Tech Ltd 1,2,4-derivati oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
UA124694C2 (uk) 2018-01-10 2021-10-27 Ідорсія Фармасьютікалз Лтд 2,4,6,7-ТЕТРАГІДРОПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ОНОВІ ПОХІДНІ ТА СПОРІДНЕНІ СПОЛУКИ ЯК МОДУЛЯТОРИ РЕЦЕПТОРА C5A ДЛЯ ЛІКУВАННЯ ВАСКУЛІТУ ТА ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
WO2019141803A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51125286A (en) * 1975-02-14 1976-11-01 Yoshitomi Pharmaceut Ind Ltd A process for preparing novel 3- substituted n-benzylpyrrolidine deriv atives

Also Published As

Publication number Publication date
CA3087886A1 (en) 2019-07-25
JP2021511324A (ja) 2021-05-06
WO2019141803A1 (en) 2019-07-25
US20200347029A1 (en) 2020-11-05
US11739070B2 (en) 2023-08-29
JP7281469B2 (ja) 2023-05-25
EP3740476A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
JP7281469B2 (ja) C5a受容体調節剤
TWI802591B (zh) 具有環狀構造的化合物
TWI774905B (zh) C5a受體調節劑
ES2972509T3 (es) Derivados de (hetero)aril-metil-tio-beta-D-galactopiranósidos
US20100190762A1 (en) Triazolyl phenyl benzenesulfonamides
AU2023416218A1 (en) Protein tyrosine kinase inhibitor and medical use thereof
JP7281470B2 (ja) C5a受容体調節剤
HK40035648B (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds for treating vasculitis and inflammatory diseases
HK40035648A (en) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-one derivatives and related compounds for treating vasculitis and inflammatory diseases
BR112020013788B1 (pt) Composto, composição farmacêutica, e, uso de um composto
TW202613096A (zh) 氘代的Hedgehog通路SMO受體抑制劑
EA042931B1 (ru) 2,4,6,7-ТЕТРАГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-5-ОНОВЫЕ ПРОИЗВОДНЫЕ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА C5A ДЛЯ ЛЕЧЕНИЯ ВАСКУЛИТА И ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200901